S-1/A: Accelerate Diagnostics Announces Public Offering of Units and Warrants

Accelerate Diagnostics plans to offer 4,500,000 units, each with a share of common stock and a warrant, along with pre-funded units for certain investors.

Summary

• Accelerate Diagnostics is planning a public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock.
• Pre-funded units, each consisting of one pre-funded warrant and one warrant, will also be offered to investors who would otherwise exceed beneficial ownership limits.
• The offering includes up to 9,000,000 shares of common stock underlying the warrants and pre-funded warrants.
• The largest shareholder, the Jack W. Schuler Living Trust, has agreed to backstop the offering up to $10 million.
• The company intends to use the net proceeds to fund its Wave program through initial FDA 510(k) submission and for working capital and for general corporate purposes.

Sentiment

Score: 5

Explanation: Neutral sentiment. The announcement details a capital raising activity, which can be viewed as both positive (securing funding) and negative (potential dilution). The company's financial situation and the risks associated with the business temper any strong positive outlook.

Positives

• The Jack W. Schuler Living Trust's backstop agreement provides a level of financial security for the offering.
• Funding will be used to advance the Wave program, a next generation AST platform.

Risks

• There is no established trading market for the Warrants or the Pre-Funded Warrants.
• The company's financial condition, including its substantial indebtedness, raises substantial doubt regarding its ability to continue as a going concern.
• The company has substantial indebtedness, which could have important consequences to its business.
• The company is in default of payment obligations under the terms of its 2.50% convertible senior notes (2.50% Notes), which matured on March 15, 2023 and became due and payable.
• The company has limited revenues from its products and no assurance of future revenues.
• The company has a history of losses and expect to continue to incur losses in the future, and we cannot be certain that we will achieve or sustain profitability.

Future Outlook

The company intends to use the proceeds of this offering to fund its Wave program through initial FDA 510(k) submission and for working capital and for general corporate purposes.

Industry Context

The announcement highlights the ongoing need for rapid diagnostic solutions in the face of increasing antibiotic resistance, a key concern in the healthcare industry.

Related Party Transactions

• The Jack W. Schuler Living Trust, a major shareholder and entity affiliated with a director, has committed to backstopping the offering up to $10 million.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's ability to execute its business plan and develop new products will be enhanced by the capital raised.
• Customers may benefit from the development of the Wave system and other product enhancements.

Next Steps

• File the Prospectus with the SEC.
• Obtain necessary approvals from Nasdaq to list the Shares and Warrant Shares.
• Complete the sale of Units and Pre-Funded Units to investors.
• Advance the Wave program through initial FDA 510(k) submission.

Key Dates

Keywords

public offering, units, warrants, Accelerate Diagnostics, common stock, pre-funded warrants, backstop, Wave program, Jack W. Schuler Living Trust